Intelligent Bio Solutions Inc. (INBS)
| Previous Close | 2.6600 |
| Open | 2.7800 |
| Bid | 2.5300 x 300 |
| Ask | 2.6000 x 100 |
| Day's Range | 2.5700 - 2.7800 |
| 52 Week Range | 2.2800 - 44.8800 |
| Volume | |
| Avg. Volume | 1,738,966 |
| Market Cap | 7.395M |
| Beta (5Y Monthly) | 4.83 |
| PE Ratio (TTM) | 0.04 |
| EPS (TTM) | 64.6800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
GlobeNewswireIntelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisitionNEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal third
- GlobeNewswire
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus Cartridge Reader. This latest achievement follows the succe
- GlobeNewswire
Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City. LD Micro Invitational XIV Investment ConferenceDates: April 8-9, 2024Location: Sof
